Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAIL: Glofitamab in a Response Adapted Approach for DLBCL
NCT06050694Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- Jan 2025
- Primary completion
- Nov 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by University Health Network. Started Jan 2025; status: recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06050694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06050694.